在患有MET外显子14跳转突变或放大 (KCSG AL19-17) 的晚期固体癌症患者中进行tepotinib的II期研究
1Division of Hematology-Oncology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul.
ESMO open
|August 30, 2024
概括
在MET外显子14跳转突变或在各种癌症中进行MET放大的患者中,特波提尼布显示出显著的抗瘤活性. 基于等离子体的下一代测序可能有助于预测治疗反应.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 研究了tepotinib在具有MET外显子14跳转突变 (METex14) 或MET基因放大的固体瘤中的疗效和安全性.
- 专注于高级或转移性癌症的标准治疗后治疗.
研究的目的:
- 为了评估tepotinib在MET失调患者的客观反应率 (ORR) 和生存结果.
- 探索血下一代测序 (NGS) 检测MET失调和预测治疗反应的实用性.
主要方法:
- 在35名患有晚期固体瘤的患者中进行tepotinib的II期多中心研究.
- 通过基于组织的NGS证实了METex14或MET放大.
- 使用血NGS进行基因配置文件的探索性分析.
主要成果:
- 整体ORR为57.6%;METex14为52.2%,MET放大为70%.
- 无进展生存时间 (PFS) 中位数为8个月,总生存时间 (OS) 中位数为14个月.
- 血NGS检测到MET失调的ORR为72.2%,而没有检测的ORR为30%. 副作用通常是轻微的.
结论:
- 德波提尼布在METex14中表现出一致的抗瘤活性,并在各种癌症中对MET放大有前途的活性.
- 基于等离子体的MET失调检测可以预测tepotinib的反应.
- 德波提尼布对于具有特定MET变化的患者来说是一种潜在的治疗选择.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
09:02Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
11.9K
相关概念视频
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K